Debrisoquine Oxidation Polymorphism in Patients with Chronic Inflammatory Bowel Disease

References

• Shivananda S, Mayberry J F. Epidemiology of inflammatory bowel disease. Curr Opin Gastroenterol 1993; 9: 560–5
   Web of Science ®Google Scholar
• Vilardell F, Sancho F J, Roca M, Pujol J. Colitis ulcerosa: aspectos médicos. Enfermedades Digestivas, F Vilardell, J Rodés, J R Malagelada, et al. CEA SA, Madrid 1990; 1311–42
   Google Scholar
• Kuster W, Pascoe L, Purman J, et al. The genetics of Crohn's disease: complex segregation analysis of a family study with 256 patients with Crohn's disease and 5387 relatives. Am J Med Genet 1989; 32: 105–8
   PubMed Web of Science ®Google Scholar
• Meucci G, Vecchl M, Torgano G, et al. Familial aggregation of inflammatory bowel disease in Northern Italy: a multicenter study. Gastroenterology 1992; 103: 514–9
   PubMed Web of Science ®Google Scholar
• Probert C SJ, Jayanhi V, Hughes A O, Thompson J R, Wicks A CB, Mayberry J F. Prevalence and family risk of ulcerative colitis and Crohn's disease: an epidemiological study among Europeans and South Asians in Leicestershire. Gut 1993; 34: 1547–51
   PubMed Web of Science ®Google Scholar
• Price-Evans D A, Mahgoub A, Sloan T P, Idle J R. A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population. J Med Genet 1980; 17: 102–5
   PubMed Web of Science ®Google Scholar
• Broly F, Gaedigk A, Heim M, Eichelbaum M, Morike K, Meyer U A. Debrisoquine/sparteine hydroxylation genotype and phenotype: analysis of common mutations and alleles of CYP2D6 in a European population. DNA Cell Biol 1991; 10: 545–58
   PubMed Web of Science ®Google Scholar
• Caporaso N, Landt M T, Vineis P. Relevance of metabolic polymorphism to human carcinogenesis: evaluation of epidemiologic evidence. Pharmacogenetics 1991; 1: 4–19
   PubMedGoogle Scholar
• Kallio J, Marttila R J, Rinne U K, Sonninen V, Syvälahti E. Debrisoquine oxidation in Parkinson's disease. Acta Neurol Scand 1991; 83: 194–7
   PubMed Web of Science ®Google Scholar
• Baer A N, McAllister C B, Wilkinson G R, Woosley R L, Pincus T. Altered distribution of debrisoquine oxidation phenotypes in patients with systemic lupus erythematosus. Arthritis Rheum 1986; 29: 843–50
   PubMed Web of Science ®Google Scholar
• Benitez J, Ladero J M, Andres M P, Jover J A, Morado C, Bañares A. Debrisoquine oxidation polymorphism in patients with rheumatoid arthritis. Ann Rheum Dis 1994; 53: 211–3
   PubMed Web of Science ®Google Scholar
• Fonne-Pfister R, Meyer U A. Xenobiotic and endobiotic inhibitors of cytochrome P-450db1 function, the target of the debrisoquine/sparteine type polymorphism. Biochem Pharmacol 1988; 37: 3829–35
   PubMed Web of Science ®Google Scholar
• Lennard M S, Silas J H, Smith A J, Tucker G T. Determination of debrisoquine and its 4-hydroxy metabolite in biological fluids by gas chromatography with flame-ionization and nitrogen-selective detection. J Chromatogr 1977; 133: 161–5
   PubMed Web of Science ®Google Scholar
• Dahl M L, Johanson I, Palmerts M P, Ingelman-Sundberg M, Sjöqvist F. Analysis of the CYP2D6 gene in relation to debrisoquin and desimipramine hydroxylation in a Swedish population. Clin Pharmacol Ther 1992; 51: 12–7
   PubMed Web of Science ®Google Scholar
• Stelner E, Isellus L, Alvan G, Lindsten J, Sjoqvist F. A family study of genetic and environmental factors determining polymorphic hydroxylation of debrisoquin. Clin Pharmacol Ther 1985; 38: 394–401
   PubMed Web of Science ®Google Scholar
• Mura C, Panserat S, Vincent-Viry M, Galteau M M, Jacqz-Aigrain E, Krishnamoorthy R. DNA haplotype dependency of debrisoquine 4-hydroxylase (CYP2D6) expression among extensive metabolisers. Hum Genet 1993; 92: 367–72
   PubMed Web of Science ®Google Scholar
• Slegmund W, Hanke W, Zschiesche M, Franke G, Biebler K E, Wilke A. N-acetylation and debrisoquine type oxidation polymorphism in Caucasians — with reference to age and sex. Int J Clin Pharmacol Ther Toxicol 1990; 12: 504–9
   Google Scholar
• Vincent-Viry M, Muller J, Fournier B, Galteau M M, Slest G. Relation between debrisoquine oxidation phenotype and morphological, biological, and pathological variables in a large population. Clin Chem 1991; 37: 327–32
   PubMed Web of Science ®Google Scholar
• Agúndez J AG, Martínez C, Ladero J M, et al. Debrisoquin oxidation genotype and susceptibility to lung cancer. Clin Pharmacol Ther 1994; 55: 10–4
   PubMed Web of Science ®Google Scholar
• Agúndez J AG, Jimenez-Jimenez F J, Luengo A, et al. Association between the oxidative polymorphism and early onset of Parkinson's disease. Clin Pharmacol Ther, (in press)
   Google Scholar
• Agúndez J AG, Ledesma M C, Benitez J, et al. CYP2D6 genes and risk of liver cancer. Lancet 1995; 345: 830–1
   PubMed Web of Science ®Google Scholar